<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04061486</url>
  </required_header>
  <id_info>
    <org_study_id>1904-SEV-050-CR</org_study_id>
    <nct_id>NCT04061486</nct_id>
  </id_info>
  <brief_title>Sperm Separation Efficiency to Maximize Pregnancy Rates: MACS vs. FERTILE Chip</brief_title>
  <acronym>FERTIMACS</acronym>
  <official_title>Sperm Separation Efficiency to Maximize Pregnancy Rates: MACS vs. FERTILE Chip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IVI Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IVI Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In assisted reproductive technology (ART), the diagnosis of male infertility has been
      conducted based on the assessment and analysis of sperm concentration, motility and
      morphology with the aim of obtaining the best quality of spermatozoa. Any type of damage
      present in sperm DNA can lead to ART failure. Sperm DNA fragmentation might be the most
      frequent cause of paternal DNA anomaly transmitted to offspring, and is found in a variable
      percentage of spermatozoa in subfertile and infertile men. Such DNA fragmentation is
      negatively correlated with semen quality and consequently, there is a need to develop sperm
      separation techniques that facilitate retrieval of as many spermatozoa with normal DNA
      integrity as possible from ejaculated semen.

      Because of centrifugation steps associated to swim-up or density-gradient can induce sperm
      DNA fragmentation via reactive oxygen species (ROS), microfluidic sperm sorters are being
      used to isolate motile human spermatozoa based on fluid dynamics. It seems to be that using
      this separation method, spermatozoa do not undergo added physical stress from sources such as
      a centrifuge. Hence, this new technology has been proposed to minimize DNA damage. In this
      study, we aim to determine if microfluidic sorting improves the selection of the best
      functional and with lower DNA fragmentation spermatozoa when compared to magnetic activated
      cell sorting (MACS) in split semen samples, and increases clinical outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>Mar 2019 - Oct 2021</time_frame>
    <description>Total of positive pregnancies / total of patients with embryo transfer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>Mar 2019 - Oct 2021</time_frame>
    <description>Total of oocyte fertilized / total of oocyte injected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>Mar 2019 - Oct 2021</time_frame>
    <description>Total of implanted embryos / total of transferred embryos</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blastocyst rate</measure>
    <time_frame>Mar 2019 - Oct 2021</time_frame>
    <description>Total of bastocyst / total of oocyte fertilized</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Infertility, Male</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <description>One half of the oocyte cohort is microinjected with sperm selected by the Fertile technique, while the other half of the patient's oocyte cohort is microinjected with sperm selected by the MACS technique.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Infertile patients needing an IVF treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Oocyte recipient patients

        Exclusion Criteria:

          -  Sperm concentration &lt; 5 Mill/ml

          -  Percentage of motile sperm &lt; 15%
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina González Ravina, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI RMA Seville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina González Ravina, PhD</last_name>
    <phone>954286274</phone>
    <email>cristina.gonzalez@ivirma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esther Santamaría-López, MSc</last_name>
    <phone>954286274</phone>
    <email>esther.santamaria@ivirma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IVI RMA Seville</name>
      <address>
        <city>Seville</city>
        <zip>41011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Santamaría-López, MSc</last_name>
      <phone>954286274</phone>
      <email>esther.santamaria@ivirma.com</email>
    </contact>
    <contact_backup>
      <last_name>Cristina González Ravina, PhD</last_name>
      <phone>954286274</phone>
      <email>cristina.gonzalez@ivirma.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>August 16, 2019</last_update_submitted>
  <last_update_submitted_qc>August 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MACS</keyword>
  <keyword>DNA fragmentation</keyword>
  <keyword>Sperm selection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

